Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
Maximilian Stahl(Harvard University), Marlise R. Luskin(Dana-Farber Cancer Institute), Kelly Ling(Dana-Farber Cancer Institute), Kevin Copson(Dana-Farber Cancer Institute), Eric S. Winer(Providence College), Martha Wadleigh(Dana-Farber Cancer Institute), Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Gerard Giblin(Mater Misericordiae University Hospital), Richard M. Stone(Dana-Farber Cancer Institute), R. Coleman Lindsley(Harvard University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yiwen Liu(University of Arizona), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Anne Charles(Dana-Farber Cancer Institute), Anju Nohria(Brigham and Women's Hospital)
Cited by 5
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k